The influence of percutaneous atrial septal defect closure on the occurrence of migraine
|
|
- Gloria Osborne
- 5 years ago
- Views:
Transcription
1 European Heart Journal (2005) 26, doi: /eurheartj/ehi170 Clinical research The influence of percutaneous atrial septal defect closure on the occurrence of migraine Katrin Mortelmans 1, Martijn Post 1, Vincent Thijs 2, Luc Herroelen 2, and Werner Budts 1 * 1 Department of Cardiology, Internal Medicine, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; and 2 Department of Neurology, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium Received 19 August 2004; revised 13 January 2005; accepted 20 January 2005; online publish-ahead-of-print 3 March 2005 This paper was guest edited by Per G. Bjornstad, Rikshospitalet, The National Hospital, Oslo, Norway KEYWORDS Migraine; Atrial septum defect; Transcatheter closure; Amplatzer device Introduction A causal relationship between the presence of migraine and a right-to-left shunt has been proposed. 1 3 Wilmshurst and Nightingale hypothesized that trigger substances in the venous circulation could pass through the interatrial septum and induce migraine attacks. These trigger substances should usually be filtered in the lungs, but in the presence of the right-to-left shunt the lungfilter may be bypassed. 4 This could explain the higher prevalence of a patent foramen ovale (PFO) in patients suffering from migraine. Moreover, it has been reported that closing an interatrial communication (mainly PFO) reduces migraine with aura and has a variable effect on migraine without aura. 2,5 8 Therefore, we were interested in determining the effect of percutaneous atrial septal defect (ASD) closure on the occurrence of migraine. * Corresponding author. Tel: þ ; fax: þ address: werner.budts@uz.kuleuven.ac.be Aims Percutaneous patent foramen ovale closure seems to influence migraine. We wanted to observe the effect of percutaneous atrial septal defect (ASD) closure on migraine. Methods and results All patients (.16 years of age) with a percutaneous ASD closure were selected from our database (n ¼ 114). A questionnaire about headache before and after closure was sent. According to the criteria of the International Headache Society, two neurologists diagnosed migraine with and without aura (MAþ and MA2, respectively). McNemar paired x 2 and Wilcoxon signed rank tests were used where applicable. Seventy-five patients (66%, 59 females, mean age years) responded and were included in the study. An Amplatzer ASD occluder was used in all. Median follow-up time was 29 months (IQ1 and IQ3, 18 and 39 months, respectively). The prevalence of MA2 and MAþ changed from 19 (14/75) and 11% (8/75), respectively, before closure to 12 (9/75) and 15% (11/75), respectively, after closure (P ¼ 0.18 and P ¼ 0.55, respectively, vs. before closure). In 12 patients who suffered from migraine before closure (n ¼ 4 and 8, MAþ and MA2, respectively), migraine disappeared. In this subgroup, the frequency of migraine attacks decreased significantly (P ¼ 0.01). New-onset migraine was noted in 10 patients (n ¼ 7 and 3, MAþ and MA2, respectively). Conclusion Percutaneous ASD closure was not related to a decrease in prevalence of migraine. In a subgroup, patients who suffered from typical migraine before ASD closure, the frequency of migraine attacks decreased significantly. The reason for the new-onset migraine remains unexplained. A larger study sample will be necessary to determine these findings. Methods Patient selection All patients with a minimum age of 16 years, who underwent a percutaneous ASD closure in our centre between July 1999 and September 2003, were selected for the study. Patients were identified through the database of Congenital Cardiology, in which all percutaneous ASD closures of our hospital are registered. The medical files of these patients were reviewed with focus on the haemodynamic measurements and closing procedure of the ASD. The protocol of the study was approved by the institute s Ethics Committee, and all subjects gave informed consent. Evaluation of migraine A structured questionnaire was composed in collaboration with the Department of Neurology in a way such that a neurologist could diagnose migraine with or without aura, according to the International Headache Society. 9,10 The questionnaire was sent to all patients. They were asked about the presence, frequency, severity, duration, type, and site of headache. They were also interrogated about the occurrence of scotoma, paresthesia, paresis, aphasia, aggravating factors, accompanying symptoms such as nausea, vomiting, sono- and/or photophobia, and whether they where able to proceed daily activities. For the frequency of & The European Society of Cardiology All rights reserved. For Permissions, please journals.permissions@oupjournals.org
2 1534 K. Mortelmans et al. migraine attacks, the relative frequency had to be reported by the patients (score from 0 to 7, no headache episodes to daily episodes, respectively, Figure 1). The questions focussed on three time periods: before, at 2 months, and at least 6 months after ASD closure. The patients were asked to send the questionnaire back, a prepaid envelope was enclosed. Two independent neurologists diagnosed migraine with and without aura (MAþ and MA2, respectively), before, at 2 months, and at least 6 months after closure, both blinded to the patients files and time periods. Statistical analysis Figure 1 Descriptive statistics was used to report patients and follow-up characteristics. Continuous variables with normal distribution were presented as mean + standard deviation. Median, first, and third quartiles (IQ1 and IQ3) were used when normal distribution was absent. McNemar paired x 2 test was performed to describe changes in proportions of patients with migraine. Kaplan Meier survival analysis was used to estimate the median time to migraine Translated example of the headache questionnaire. occurrence after ASD closure. Wilcoxon signed rank test was performed to compare migraine characteristics before and after ASD closure. One-way ANOVA and Tukey s honestly significant difference test were used to determine the differences between the haemodynamic parameters of the subgroups of patients. Interobserver reliability was evaluated by the Kappa coefficient. P, 0.05 was considered to be statistically significant. Results Patient characteristics One hundred and fourteen patients with ASD closure could be identified through the database of Congenital Cardiology. Seventy-five patients (66%, 59 females, mean age years) sent the questionnaire back and could finally be included in the study. Mean body weight and mean length of the study population were kg and cm, respectively.
3 ASD and migraine 1535 Table 1 ASD characteristics in relationship with migraine before percutaneous closure Entire study population (n ¼ 75) No migraine (n ¼ 53) MAþ (n ¼ 8) MA2 (n ¼ 14) Age (years) RA pressure (mmhg) RV systolic pressure (mmhg) RV diastolic pressure (mmhg) PA systolic pressure (mmhg) PA diastolic pressure (mmhg) PA mean pressure (mmhg) Q p /Q s (ratio) Balloon sized defect size (mm) Figure 2 RA, right atrium; RV, right ventricle; PA, pulmonary artery; Q p /Q s, ratio pulmonary cardiac output/systemic cardiac output. P ¼ 0.01 vs. no migraine (Tukey s post hoc test). Histogram of the different sizes of the Amplatzer ASD occluder. All ASDs where closed with the Amplatzer ASD occluder (AGA Medical Corporation, MN, USA). The haemodynamic measurements obtained during right heart catheterization are summarized in Table 1. The histogram of the different sizes of Amplatzer ASD occluders is given in Figure 2. Changes in prevalence of migraine Median follow-up time of the entire study was 29 months (IQ1 and IQ3, 18 and 39 months, respectively). Before ASD closure, typical MAþ was present in eight (8/75) and MA2 in 14 patients (14/75), a prevalence of 11 and 19%, respectively. Two months after closure, the prevalence of MAþ was changed into 15%. In four out of eight patients, who suffered from MAþ before closure, MAþ disappeared. However, seven patients who had no migraine before developed MAþ at 2 months after the procedure. In the same time period, the prevalence of MA2 changed into 13%. In six out of 14 patients who suffered from MA2 before closure, MA2 disappeared. However, two patients who had no migraine before developed MA2 at 2 months after the closing procedure. None of these changes in prevalence was statistically significant (P ¼ 0.55 and P ¼ 0.51 for MAþ and MA2, respectively, vs. before closure). The data for at least 6 months after the procedure were available for all patients, and the median time to the occurrence of migraine (MAþ or MA2) after ASD closure was 48 months (95% CI months). The prevalence of MAþ remained 15% and no changes were reported between 2 Table 2 Changes in number of patients with migraine after ASD closure (n ¼ 75) Before closure After closure At 2 months No migraine MA2 Persistent MA New-onset MA2 2 3 MAþ Persistent MAþ New-onset MAþ 7 7 Values are number of patients. At least 6 months and 6 months. The prevalence of MA2 at least 6 months after closure was 12%. After at least 6 months, eight of 14 patients who had MA2 before closing procedure did not have MA2 anymore. However, three patients who did not have migraine before developed migraine in the time period of at least 6 months. None of these changes in prevalence was statistically significant (P ¼ 0.55 and P ¼ 0.18 for MAþ and MA2, respectively, vs. before closure). These data are summarized in Table 2. The interobserver reliability was high (kappa coefficient ¼ 0.7, P ¼ 0.045). Characteristics of migraine before and at least 6 months after ASD closure In the overall group of patients who suffered from migraine before ASD closure (MAþ and MA2, n ¼ 8 and 14, respectively), the median duration of migraine attacks in patients who still suffered from migraine at least 6 months after closure (MAþ and MA2, n ¼ 4 and 6, respectively) decreased from 270 min (IQ1 and IQ3, 90 and 2280 min, respectively) before to 120 min (IQ1 and IQ3, 60 and 270 min, respectively) at least 6 months after ASD closure (P ¼ 0.24). In these patients, the severity of migraine attacks remained unchanged. The median severity score (on a scale ranging from 0 to 10, minimal to very severe pain, respectively) was 2 (IQ1 and IQ3, 1 and 4, respectively) before and after ASD closure (P ¼ 0.41). The median scores
4 1536 K. Mortelmans et al. indicating the frequency of migraine attacks in the entire group of patients who suffered from migraine before ASD closure were 3 (IQ1 and IQ3, 2 and 4, respectively) before and 3 (IQ1 and IQ3, 0 and 4, respectively) at least 6 months after ASD closure. Although the median scores were similar, Wilcoxon signed rank test was statistically significant (P ¼ 0.01). The latter score was calculated from a scale ranging from 0 to 7 (from no headache to headache s several times per day). Relationship between ASD characteristics before closure and migraine Table 1 summarizes the haemodynamic characteristics of the ASDs before closure. The entire study population is divided in three subgroups (patients without migraine, MAþ, and MA2). No significant differences could be identified among the three subgroups, except for MA2 patients who were significantly younger than patients with no migraine (P ¼ 0.01). MAþ patients were also younger than patients with no migraine, but significant statistical difference was not reached. Table 3 summarizes the haemodynamic characteristics of the ASDs after closure. For this purpose, the entire study population was split into four subgroups (patients in whom no migraine was present during the study, patients who developed migraine after ASD closure, patients in whom migraine disappeared after percutaneous intervention, and patients in whom migraine persisted). Patients in whom no migraine was present during the entire study were significantly older than patients in whom migraine persisted or developed (P ¼ and P ¼ 0.045, respectively). In addition, the devices used for closure were significantly smaller in patients in whom no migraine was present during the entire study and in whom migraine disappeared when compared with the sizes of devices used in patients in whom migraine developed and persisted, respectively (P ¼ 0.01 and P ¼ 0.004, respectively). Discussion We found in patients with a secundum type ASD a prevalence of migraine of 30%. Eleven per cent suffered from MAþ and Table 3 ASD characteristics in relationship with migraine after percutaneous closure No migraine before and after (n ¼ 43) 19% from MA2. After percutaneous closure with the Amplatzer ASD occluder, the overall prevalence of migraine remained unchanged. However, we found that the frequency of migraine attacks in patients with migraine before closure decreased significantly for a mean follow-up period of at least 2 years. In addition, a substantial number of patients developed migraine after ASD closure. These patients were relatively younger and bigger devices were used when compared with patients in whom migraine disappeared. The prevalence of migraine in the overall population is 6% in men and 15 18% in women A higher prevalence of PFO is reported in patients with migraine when compared with the general population, vs. 25%. 1 3 In addition, we reported recently a higher prevalence of migraine in patients with a PFO. 7 All this suggests a causal relationship between the presence of PFO and migraine. Some authors hypothesize that a particular genetic substrate might determine both atrial septum abnormalities and migraine. 15 However, migraine is a form of neurovascular headache, in which not only neural events but also vasoactive trigger substances might play an important role. 16 Wilmshurst and Nightingale 4 suggested that trigger substances in the venous circulation could pass through a PFO. Normally, these trigger substances will be filtered in the lungs. In individuals with a right-to-left shunt, a lower dose of trigger substances is needed to induce migraine attacks because the shunt permits the lungfilter to be bypassed. In individuals without a right-to-left shunt, a larger amount of trigger substances is needed to induce migraine by overwhelming the filter capacity of the lungs. Micro-emboli and vasoactive chemicals such as serotonin are proposed as potential trigger substances. This hypothesis might explain why recent studies report a decrease in prevalence and the severity of migraine after PFO closure. 7,8 Until now no isolated data have been published about the relationship between migraine and the presence of an ASD. Although an ASD is mainly characterized by a left-to-right shunt and volume overload of the right heart, a small right-to-left shunt may occur during Valsalva or exercise. Theoretically, this right-to-left shunt could also permit that the lungfilter is bypassed. Indeed, we found a relatively high prevalence of migraine in patients with an unclosed secundum type ASD (up to 30%). This seems to be higher Migraine persisted (n ¼ 10) Migraine developed (n ¼ 10) Migraine disappeared (n ¼ 12) Age (years) RA (mmhg) RV systolic pressure (mmhg) RV diastolic pressure (mmhg) PA systolic pressure (mmhg) PA diastolic pressure (mmhg) PA means pressure (mmhg) Q p /Q s (ratio) Defect size (mm) } RA, right atrium; RV, right ventricle; PA, pulmonary artery; Q p /Q s, ratio pulmonary cardiac output/systemic cardiac output. P ¼ vs. migraine persisted. P ¼ vs. migraine developed. P ¼ vs. migraine persisted. } P ¼ vs. migraine disappeared (Tukey s post hoc test).
5 ASD and migraine 1537 than in the general population, but lower than in patients with a PFO. 7 The latter can be explained in different ways. First, in patients with a PFO, the right-to-left shunt is obligate; whereas in patients with an ASD, the left-toright shunt predominates and permits less vaso-active agents passing through the interatrial septum. Indeed, in almost all studies where the occurrence of migraine is influenced by percutaneous closure, a clinical event related to a obligate right-to-left shunt was present. 7,8 Secondly, the age distribution of our ASD population differed slightly from PFO populations 7,8 and could explain differences in prevalence of migraine. We found that ASD patients with migraine were younger than patients with no migraine, and that MAþ were older than MA2 patients. The latter may support the hypothesis that MAþ in older patients (more prone for thrombus formation in the venous circulation) could be related with a right-to-left shunt through an interatrial communication. Indeed, in a subgroup analysis after ASD closure, migraine disappeared only in the relatively older patient (.50 years of age). In contrast to PFO closure, we found no significant changes in the overall prevalence of MAþ or MA2 after ASD closure. Nevertheless, in several patients MAþ or MA2 disappeared after closure, but in an almost equal number of patients MAþ and MA2 developed. However, in the subgroup of patients with migraine before closure, the frequency of migraine attacks decreased and remained decreased for a median follow-up time of at least 2 years. The latter excludes the influence of drugs or a possible placebo effect. The reason why patients developed migraine after percutaneous ASD closure remains unexplained. Yankovsky and Kuritzky 17 reported aggravation of MAþ into a daily pattern after ASD closure and suggested that elevated or changed levels of atrial natriuretic peptide as a consequence of intra-atrial pressure imbalance immediately after closure could play an important role for the explanation of their findings. Others believe more in a disturbed circadian variation of a basic physiologic process. 18 Moreover, it is not excluded that on the left sided disk of the Amplatzer device micro-thrombi may be formed and micro-embolize in the systemic circulation. The finding that relatively bigger devices were used in patients who developed migraine or in whom migraine persisted when compared with patients in whom migraine disappeared, may support this hypothesis. However, the explanation of the changes in incidence of migraine remains speculative in the absence of large prospective randomized trials. Finally, we want to apply a few limitations to our study. First, a selection bias might be present because our patient population was a selected cohort referred to our centre for percutaneous ASD closure and 34% of the selected patients did not send the questionnaire back. Secondly, it was a retrospective study in which patients were asked about their headache before and after ASD closure. It might be difficult for the patients to remember the characteristics of headache before and after ASD closure. Therefore, a recall bias might be introduced. Thirdly, the study was underpowered to detect significant differences in MA2 and MAþ characteristics. In conclusion, percutaneous ASD closure was not related to a decrease in prevalence of migraine. However, in the subgroup patients who suffered from typical migraine before ASD closure, the frequency of migraine attacks decreased significantly. These data fit with the hypothesis that vaso-active agents passing through the interatrial septum might play a role in the occurrence of migraine. The reason for the new-onset migraine remains unexplained. A larger study sample will be necessary to confirm and analyse these findings. References 1. Del Sette M, Angeli S, Leandri M, Ferriero G, Bruzzone GL, Finocchi C, Gandolfo C. Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovasc Dis 1998;8: Sztajzel R, Genoud D, Roth S, Mermillod B, Le Floch-Rohr J. Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. Cerebrovasc Dis 2002;13: Anzola GP. Clinical impact of patent foramen ovale diagnosis with transcranial Doppler. Eur J Ultrasound 2002;16: Wilmshurst P, Nightingale S. Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin Sci (Lond) 2001;100: Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 2000;356: Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E. Transcatheter closure of patent foramen ovale: a new migraine treatment? J Interv Cardiol 2003;16: Post MC, Thijs V, Herroelen L, Budts WI. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004;62: Schwerzmann M, Wiher S, Nedeltchev K, Mattle HP, Wahl A, Seiler C, Meier B, Windecker S. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004;62: Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8: Goadsby PJ, Olesen J. Diagnosis and management of migraine. BMJ 1996;312: Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994;44:S17 S Lusic I. Population variation in migraine prevalence the unsolved problem. Coll Antropol 2001;25: Lipton RB, Stewart WF, Reed M, Diamond S. Migraine s impact today. Burden of illness, patterns of care. Postgrad Med 2001;109:38 40, Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2003;23: Arquizan C, Coste J, Touboul PJ, Mas JL. Is patent foramen ovale a family trait? A transcranial Doppler sonographic study. Stroke 2001; 32: Goadsby PJ, Lipton RB, Ferrari MD. Migraine current understanding and treatment. N Engl J Med 2002;346: Yankovsky AE, Kuritzky A. Transformation into daily migraine with aura following transcutaneous atrial septal defect closure. Headache 2003;43: Gupta V. Closure of atrial septal defect and migraine. Headache 2004;44:291.
PFO Closure for the Management of Migraine and Stroke
PFO Closure for the Management of Migraine and Stroke Sun U. Kwon Department of Neurology, Asan Medical Center, UUMC Contents PFO & Migraine PFO causes Migraine or Not? PFO closure for Migraine PFO & Stroke
More informationPatent Foramen Ovale: Diagnosis and Treatment
Patent Foramen Ovale: Diagnosis and Treatment Anthony DeMaria Judy and Jack White Chair in Cardiology University of California, San Diego At one time or another a Grantee, Sponsored Speaker or Ad-hoc Consultant
More informationPERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL
PERCUTANEOUS CLOSURE OF PATENT FORAMEN OVALE AND ATRIAL SEPTAL DEFECT: STATE OF THE ART AND A CRITICAL APPRAISAL Carmelo Cernigliaro Clinica San Gaudenzio Novara Eco 2D e 3D Eco Transesofageo Large shunt
More informationThe Relation of Migraine Headaches and Interatrial Shunts
PFO AND MIGRAINE HOSPITAL CHRONICLES 2006, SUPPLEMENT: 73 78 CARDIOLOGY UPDATE 2006 The Relation of Migraine Headaches and Interatrial Shunts Konstantinos G. Kappos, MD, Vassiliki Tsagou, MD, George Andrikopoulos,
More informationWhy Should We Treat PFO?
Why Should We Treat PFO? SCAI Interventional Cardiology Fellows Course December 7, 2012 Jonathan Tobis, MD Director of Interventional Cardiology UCLA Disclosures Jonathan Tobis, MD 1. A Principal Investigator
More informationFabien Praz, Andreas Wahl, Sophie Beney, Stephan Windecker, Heinrich P. Mattle*, Bernhard Meier
Procedural Outcome after Percutaneous Closure of Patent Foramen Ovale using the Amplatzer PFO Occluder Without Intra-Procedural Echocardiography in 1,000 Patients Fabien Praz, Andreas Wahl, Sophie Beney,
More informationPercutaneous atrial septal defect closure with the Occlutech Figulla Flex ASD Occluder.
Percutaneous atrial septal defect closure with the Occlutech Figulla Flex ASD Occluder. First case with a novel delivery system. Werner Budts, Md, PhD, FESC Congenital and Structural Cardiology University
More informationHEADACHE & FACIAL PAIN SECTION
Pain Medicine 2014; 15: 2156 2160 Wiley Periodicals, Inc. HEADACHE & FACIAL PAIN SECTION Original Research Article An Association Between Migraines and Heart Anomalies True or False? A Heart Ultrasound
More informationGERIATRICS CASE PRESENTATION
GERIATRICS CASE PRESENTATION CASE 79 year old Patient X was admitted to hospital with SOB. He had a hx of sarcoidosis and asbestosis. Home oxygen requirement is 3-3.5litre. He was admitted, given ceftriaxone
More informationT here is an association between migraine with aura and
1315 CONGENITAL HEART DISEASE Inheritance of persistent foramen ovale and atrial septal defects and the relation to familial migraine with aura P T Wilmshurst, M J Pearson, S Nightingale, K P Walsh, W
More informationPercutaneous closure of a patent foramen ovale after cryptogenic stroke
Neth Heart J (2018) 26:5 12 https://doi.org/10.1007/s12471-017-1063-3 POINT OF VIEW Percutaneous closure of a patent foramen ovale after cryptogenic stroke R. J. R. Snijder 1 M.J.Suttorp 1 J.M.tenBerg
More informationMigraine, a recurrent headache disorder of children and adults, significantly affects quality of life and results in a substantial
Patent Foramen Ovale in Children with Migraine Headaches Rachel T. McCandless, MD, Cammon B. Arrington, MD, Douglas C. Nielsen, James F. Bale, Jr., MD, and L. LuAnn Minich, MD Objective To determine the
More informationMigraine and Patent Foramen Ovale (PFO)
Migraine and Patent Foramen Ovale (PFO) Hans-Christoph Diener Senior Professor of Clinical Neurosciences Department of Neurology and Headache Center University Essen Topics Prevalence of PFO Is migraine
More informationPredictors of unfavorable outcome after atrial septal defect closure in adults
after atrial septal defect closure in adults H. M. Gabriel 1, M. Humenberger 1, R. Rosenhek 1, GP. Diller 2, G. Kaleschke 2, TH. Binder 1, P. Probst 1, G. Maurer 1, H. Baumgartner 2 (1) Medical University
More informationBiomedical Research 2017; 28 (20): Role of atrial septal pouch (ASP) in migraine etiology. ISSN X
Biomedical Research 207; 28 (20): 8608-862 ISSN 0970-938X www.biomedres.info Role of atrial septal pouch (ASP) in migraine etiology. Murat Yilmaz, Metin Yilmaz 2, Mustafa Gokhan Vural 3, Riza Sarper Okten
More informationPFO Management update
PFO Management update May 12, 2017 Peter Casterella, MD Swedish Heart and Vascular 1 PFO Update 2017: Objectives Review recently released late outcomes of RESPECT trial and subsequent FDA approval of PFO
More informationPFO- To Close for Comfort. By: Vincent J.Caracciolo, MD FACC
PFO- To Close for Comfort By: Vincent J.Caracciolo, MD FACC PATENT FORAMEN OVALE PFO- congenital lesion that frequently persists into adulthood ( 25-30%)- autopsy and TEE studies. PFO prevalence higher
More informationIndex. cardiology.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute ischemic stroke TOAST classification of, 270 Acute myocardial infarction (AMI) cardioembolic stroke following, 207 208 noncardioembolic
More informationSmall- and Moderate-Size Right-to-Left Shunts Identified by Saline Contrast Echocardiography Are Normal and Unrelated to Migraine Headache
CHEST Original Research Small- and Moderate-Size Right-to-Left Shunts Identified by Saline Contrast Echocardiography Are Normal and Unrelated to Migraine Headache Timothy D. Woods, MD, FCCP; Leanne Harmann,
More informationWhy Treat Patent Forman Ovale
Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural Heart Disease Rush University Medical Center Conclusions
More informationImaging. Lack of Association Between Migraine Headache and Patent Foramen Ovale Results of a Case-Control Study
Imaging Lack of Association Between Migraine Headache and Patent Foramen Ovale Results of a Case-Control Study Pallav Garg, MBBS, MSc; Stephen J. Servoss, MD, MSc; Justina C. Wu, MD, PhD; Zahid H. Bajwa,
More informationFoam Sclerotherapy and Patent Foramen Ovale (PFO) Gillet J-L J L (France)
Foam Sclerotherapy and Patent Foramen Ovale (PFO) Gillet J-L J L (France) Abano Terme, October 2013 1 Definition PFO is an incomplete closure of the atrial septum that results in the creation of a flap
More informationPatent Foramen Ovale Closure Without Echocardiographic Control: Use of Standby Intracardiac Ultrasound
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 4, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.05.006 Patent Foramen
More informationPFO Closure is a Therapy for Migraine PRO
PFO Closure is a Therapy for Migraine PRO Andrew Charles, M.D. Professor Director, UCLA Goldberg Migraine Program Meyer and Renee Luskin Chair in Migraine and Headache Studies Director, Headache Research
More informationPFO (Patent Foramen Ovale): Smoking Gun or an Innocent Bystander?
PFO (Patent Foramen Ovale): Smoking Gun or an Innocent Bystander? J Thompson Sullebarger, M.D. Florida Cardiovascular Institute University of South Florida Kris Letang Tedy Bruschi Bret Michaels The Atrial
More informationDescription. Page: 1 of 23. Closure Devices for Patent Foramen Ovale and Atrial Septal Defects. Last Review Status/Date: December 2014
Last Review Status/Date: December 2014 Page: 1 of 23 Description Background Patent Foramen Ovale The foramen ovale, a component of fetal cardiovascular circulation, consists of a communication between
More informationAtrial Septal Defect Closure. Stephen Brecker Director, Cardiac Catheterisation Labs
Stephen Brecker Director, Cardiac Catheterisation Labs ADVANCED ANGIOPLASTY Incorporating The Left Main 5 Plus Course Conflicts of Interest The following companies have supported educational courses held
More informationTranscatheter Closure of Septal Defects
Transcatheter Closure of Septal Defects Policy Number: 2.02.09 Last Review: 11/2018 Origination: 3/2007 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationPRACTICAL NEUROLOGY. An endovascular device to close a patent foramen ovale: b. Patent foram Blackwell Publishing Ltd
4 PRACTICAL NEUROLOGY Patent foram An endovascular device to close a patent foramen ovale: b FEBRUARY 2003 5 Jean-Louis Mas Service de Neurologie, Hôpital Sainte-Anne, 1 rue Cabanis, 75674 Paris Cedex
More informationStroke and ASA / FO REBUTTAL
REBUTTAL Definition of an ischemic stroke Definition of a PFO Evidence for a causal role of PFO in stroke Evidence against a role of PFO in stroke Stroke recurrencies in stroke (PFO) patients Medical treatment
More informationRESPECT Safety Findings
CO-1 SCAI Town Hall Meeting Monday, October 31, 2016 Washington, DC RESPECT Safety Findings John D. Carroll, M.D., MSCAI Professor of Medicine Cardiology University of Colorado School of Medicine University
More informationRahul Jhaveri, M.D. The Heart Group of Lancaster General Health
Rahul Jhaveri, M.D. The Heart Group of Lancaster General Health INTRODUCTION Three recently published randomized controlled trials in The New England Journal of Medicine provide new information about closure
More informationBenign Headache and Diagnosis Pathophysiology. Dr Andrew J Dowson Director of the King s Headache Service King s College Hospital London
Benign Headache and Diagnosis Pathophysiology Dr Andrew J Dowson Director of the King s Headache Service King s College Hospital London Case histories Case 1 Male, 46 y - Truck driver - Headaches since
More informationPatent foramen ovale (PFO) is composed of
PFO Closure for Prevention of Recurrent Cryptogenic Stroke The evidence base is here. BY JOHN F. RHODES, JR, MD Patent foramen ovale (PFO) is composed of overlapping portions of septum primum and septum
More information2D/3D in Evaluation of Atrial Septum
2D/3D in Evaluation of Atrial Septum Roberto M Lang, MD OSTIUM SECUNDUM ASD: 2D AND 3D TNSESOPHAGEAL ECHO 1 Biplane views 90 0 3D Acquisi on Acquire 3D volume Lang RM et al. JASE 2012;25:3 46. Right atrial
More informationEffect of Having a PFO Occlusion Device in Place in the RESPECT PFO Closure Trial
Effect of Having a PFO Occlusion Device in Place in the RESPECT PFO Closure Trial DAVID E. THALER, MD, PHD, JEFFREY L. SAVER, MD RICHARD W. SMALLING, MD, PHD, JOHN D. CARROLL, MD, SCOTT BERRY, PHD, LEE
More informationI, (Issam Moussa) DO NOT have a financial interest/arrangement t/ t or affiliation with one or more organizations that could be perceived as a real
PFO Closure: Where We Are Going to after CLOSURE I Study? Issam D. Moussa, MD Professor of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida Disclosure Statement of
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationCryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do?
Cryptogenic Stroke/PFO with Thrombophilia and VTE: Do We Know What To Do? Robert J. Sommer, MD Columbia University Medical Center New York, NY Disclosure Statement of Financial Interest Within the past
More informationEchocardiographic Guidance During Placement of the Buttoned Double-Disk Device for Atrial Septa1 Defect Closure
Echocardiographic Guidance During Placement of the Buttoned Double-Disk Device for Atrial Septa1 Defect Closure L. LUANN MINICH, M.D., and A. REBECCA SNIDER, M.D. Department of Pediatrics, C.S. Mott Children
More informationUptofate Study Summary
CONGENITAL HEART DISEASE Uptofate Study Summary Acyanotic Atrial septal defect Ventricular septal defect Patent foramen ovale Patent ductus arteriosus Aortic coartation Pulmonary stenosis Cyanotic Tetralogy
More informationBASIL D. THANOPOULOS MD, PhD Associate Professor Honorary Consultant, RBH, London, UK
TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT AND PFO BASIL D. THANOPOULOS MD, PhD Associate Professor Honorary Consultant, RBH, London, UK TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT AND PFO BASIL D.
More informationClinical Commissioning Policy Statement: Patent Foramen Ovale (PFO) Closure. April Reference: NHSCB/A09/PS/a
Clinical Commissioning Policy Statement: Patent Foramen Ovale (PFO) Closure April 2013 Reference: NHSCB/A09/PS/a NHS Commissioning Board Clinical Commissioning Policy Statement: Patent Foramen Ovale (PFO)
More informationPATENT FORAMEN OVALE: UPDATE IN MANAGEMENT OF RECURRENT STROKE KATRINE ZHIROFF, MD, FACC, FSCAI LOS ANGELES CARDIOLOGY ASSOCIATES
PATENT FORAMEN OVALE: UPDATE IN MANAGEMENT OF RECURRENT STROKE KATRINE ZHIROFF, MD, FACC, FSCAI LOS ANGELES CARDIOLOGY ASSOCIATES OBJECTIVES Review social burden and epidemiology of stroke Gender disparities
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationAtrial Septal Defects
Supplementary ACHD Echo Acquisition Protocol for Atrial Septal Defects The following protocol for echo in adult patients with atrial septal defects (ASDs) is a guide for performing a comprehensive assessment
More informationTranscatheter Closure of Cardiovascular Defects
Medical Coverage Policy Effective Date...11/15/2017 Next Review Date...11/15/2018 Coverage Policy Number... 0011 Transcatheter Closure of Cardiovascular Defects Table of Contents Related Coverage Resources
More informationThe prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients
Blackwell Publishing LtdOxford, UKCHACephalalgia0333-1024Blackwell Science, 20062006261012091213Original ArticleThe prevalence of premonitory symptoms in migrainegg Schoonman et al. The prevalence of premonitory
More informationAnaesthesia for percutaneous closure of atrial septal defects Patrick A Calvert BCh MA MRCP Andrew A Klein MBBS FRCA
Anaesthesia for percutaneous closure of atrial septal defects Patrick A Calvert BCh MA MRCP Andrew A Klein MBBS FRCA Key points Percutaneous closure is the procedure of choice for the majority of patients
More informationAntithrombotic Summit Basel 2012 Basel, 26. April Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel
Antithrombotic Summit Basel 2012 Basel, 26. April 2012 Peter T. Buser Klinik Kardiologie Unviersitätsspital Basel Background stroke = third-leading cause of death among adults 1/5 of stroke survivors require
More informationMigraine and Risk of Stroke in Young Women
A Peer Reviewed Publication of the College of Allied Health & Nursing at Nova Southeastern University Dedicated to allied health professional practice and education http://ijahsp.nova.edu Vol. 5 No. 3
More informationTranscatheter closure of interatrial
372 Br HeartJf 1994;72:372-377 PRACTICE REVIEWED Department of Paediatric Cardiology, Royal Brompton Hospital, London A N Redington M L Rigby Correspondence to: Dr A N Redington, Department of Paediatric
More informationPFO closure group total no. PFO closure group no. of males
Suppl Table. Characteristics of the five trials included in this meta-analysis. Trial name Device used for Definition of medical Primary Endpoint group total no. group no. of males group age (yrs) group
More informationTranscatheter closure of patent foramen ovale using the internal jugular venous approach
New methods in diagnosis and therapy Transcatheter closure of patent foramen ovale using the internal jugular venous approach Przemysław Węglarz 1,2, Ewa Konarska-Kuszewska 2, Tadeusz Zębik 2, Piotr Kuszewski
More informationClinical material and methods. Fukui Cardiovascular Center, Fukui, Japan
Mitral Valve Regurgitation after Atrial Septal Defect Repair in Adults Shohei Yoshida, Satoshi Numata, Yasushi Tsutsumi, Osamu Monta, Sachiko Yamazaki, Hiroyuki Seo, Takaaki Samura, Hirokazu Ohashi Fukui
More informationClinical Policy: Transcatheter Closure of Patent Foramen Ovale Reference Number: CP.MP.151
Clinical Policy: Reference Number: CP.MP.151 Effective Date: 12/17 Last Review Date: 12/17 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications
More informationCryptogenic Stroke and Migraine Headache: The Clinical Cardiologist s View
CRYPTOGENIC STROKE, MIGRAINE & PFO HOSPITAL CHRONICLES 2006, SUPPLEMENT: 67 72 CARDIOLOGY UPDATE 2006 Cryptogenic Stroke and Migraine Headache: The Clinical Cardiologist s View Harold L. Kennedy, MD A
More informationIntracardiac echocardiography: an ideal guiding tool for device closure of interatrial communications
Eur J Echocardiography (2005) 6, 92e96 Intracardiac echocardiography: an ideal guiding tool for device closure of interatrial communications Thomas Bartel a, *, Thomas Konorza a, Ulrich Neudorf b, Tiko
More informationTranscatheter Closure of Septal Defects
Transcatheter Closure of Septal Defects Policy Number: 2.02.09 Last Review: 11/2017 Origination: 3/2007 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationImplantation of Cardioverter Defibrillator After Percutaneous Closure of Atrial Septal Defect
The Ochsner Journal 10:27 31, 2010 f Academic Division of Ochsner Clinic Foundation Implantation of Cardioverter Defibrillator After Percutaneous Closure of Atrial Septal Defect Anas Bitar, MD, Maria Malaya
More informationCorporate Medical Policy
Corporate Medical Policy Congenital Heart Defect, Repair Devices File Name: Origination: Last CAP Review: Next CAP Review: Last Review: congenital_heart_defect_repair_devices 10/2000 6/2017 6/2018 6/2017
More informationPatent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS
Patent Foramen Ovale and Cryptogenic Stroke: Do We Finally Have Closure? Christopher Streib, MD, MS 11-8-18 Outline 1. Background 2. Anatomy of patent foramen ovale (PFO) 3. Relationship between PFO and
More informationMigraine and hormonal contraceptives
Migraine and hormonal contraceptives Department of Community Medicine, Systems Epidemiology University of Tromsø, November 2017 Nora Stensland Bugge Medical research student Presentation outline What is
More informationA 29-Year-Old Man With Acute Onset Blurry Vision, Weakness, and Gait Abnormality
Clinical Case of the Month A 29-Year-Old Man With Acute Onset Blurry Vision, Weakness, and Gait Abnormality Deepu Thoppil, MD; Murtuza J. Ali, MD; Neeraj Jain, MD; Sanjay Kamboj, MD; Pramilla Subramaniam,
More informationCPAG Summary Report for Clinical Panel Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke The Benefits of the Proposition Percutaneous Patent Foramen Ovale
More informationPathophysiology: Left To Right Shunts
Pathophysiology: Left To Right Shunts Daphne T. Hsu, MD dh17@columbia.edu Learning Objectives Learn the relationships between pressure, blood flow, and resistance Review the transition from fetal to mature
More informationTRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT AND PFO
TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT AND PFO BASIL D. THANOPOULOS MD, PhD Associate Professor Agios Loukas Clinic, Thessaloniki, Greece Ares Heart Center, Bucharest, Romania Honorary Consultant,
More informationΓεώργιος Δ. Κατσιμαγκλής. Αν. Διευθυντής Καρδιολογικής ΚλινικήςΝΝΑ Διευθυντής Αιμοδυναμικού Εργαστηρίου ΝΝΑ
Γεώργιος Δ. Κατσιμαγκλής Αν. Διευθυντής Καρδιολογικής ΚλινικήςΝΝΑ Διευθυντής Αιμοδυναμικού Εργαστηρίου ΝΝΑ I have no disclosures ΣΥΧΝΟΤΗΤΑ An atrial septal defect (ASD) is a deficiency of the atrial septum.
More informationCryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare
Cryptogenic Stroke: What Don t We Know Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare Financial Disclosures None Objectives Principles of diagnostic evaluation
More informationMigraine Diagnosis and Treatment: Results From the American Migraine Study II
Migraine Diagnosis and Treatment: Results From the American Migraine Study II Richard B. Lipton, MD; Seymour Diamond, MD; Michael Reed, PhD; Merle L. Diamond, MD; Walter F. Stewart, MPH, PhD Objective.
More informationPathophysiology: Left To Right Shunts
Pathophysiology: Left To Right Shunts Daphne T. Hsu, MD dh17@columbia.edu Learning Objectives Learn the relationships between pressure, blood flow, and resistance Review the transition from fetal to mature
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationCONGENITAL HEART DEFECTS IN ADULTS
CONGENITAL HEART DEFECTS IN ADULTS THE ROLE OF CATHETER INTERVENTIONS Mario Carminati CONGENITAL HEART DEFECTS IN ADULTS CHD in natural history CHD with post-surgical sequelae PULMONARY VALVE STENOSIS
More informationEffect of Low-Intensity Acenocoumarol on Frequency and Severity of Migraine Attacks
Research Submission Effect of Low-Intensity Acenocoumarol on Frequency and Severity of Migraine Attacks Elisabeth A. Wammes-van der; Heijden, PharmD; Martijn H. Smidt, MD; Cees C. Tijssen, MD, PhD; Annelies
More informationJACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 3, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 3, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/10/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.11.019 Primary
More informationEchocardiography Conference
Echocardiography Conference David Stultz, MD Cardiology Fellow, PGY-6 September 20, 2005 Atrial Septal Aneurysm Bulging of Fossa Ovalis Associated commonly with Atrial septal defect or small perforations
More informationIn 1877, Cohnheim performed a
CLINICIAN UPDATE Contemporary Management of Patent Foramen Ovale Bernhard Meier, MD; James E. Lock, MD In 1877, Cohnheim performed a necropsy on a young woman who had died from a stroke. He hypothesized
More informationOriginal Article Improving migraine by means of primary transcatheter patent foramen ovale closure: long-term follow-up
Am J Cardiovasc Dis 2012;2(2):89-95 www.ajcd.us /ISSN:2160-200X/AJCD1201001 Original Article Improving migraine by means of primary transcatheter patent foramen ovale closure: long-term follow-up Gianluca
More informationThe prevalence and characteristics of migraine among the Belgian working population
Acta neurol. belg., 2007, 107, 84-90 The prevalence and characteristics of migraine among the Belgian working population Guido MOENS 1,2, Kristien JOHANNIK 1, Chris VERBEEK 1,2 and Simon BULTERYS 1,2 1
More informationPatent Foramen Ovale Its Correlation with Other Maladies and a Review of Detection Screening
Patent Foramen Ovale Its Correlation with Other Maladies and a Review of Detection Screening Michael W Jopling, MD 1, John A Kurowski, BS, RN 2 and Suzanne M Williams, MS 2 1. Chief Medical Officer, Cardiox
More information2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.
CRYPTOGENIC STROKE: 2017 Cardiovascular Symposium A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A. CRYPTOGENIC STROKE CRYPTOGENIC: OF OBSCURE OR UNKNOWN
More informationDiversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia
Marshall University Marshall Digital Scholar Internal Medicine Faculty Research Spring 5-2004 Diversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia Ellen A. Thompson
More informationPatent Foramen Ovale May Be Causal for the First Stroke but Unrelated to Subsequent Ischemic Events
Patent Foramen Ovale May Be Causal for the First Stroke but Unrelated to Subsequent Ischemic Events Marie-Luise Mono, MD; Laura Geister, BSc; Aekaterini Galimanis, MD; Simon Jung, MD; Fabien Praz, MD;
More informationComorbidities of migraine
Comorbidities of migraine Jasna Zidverc Trajković Headache center Comorbidity is greater than coincidental association of two (or more) conditions in the same individual. Feinstein 1963 Migraine has been
More informationPREVALENCE BY HEADACHE TYPE
CLINICAL CLUES AND CLINICAL RULES: PRIMARY VS SECONDARY HEADACHE * Based on a presentation by David W. Dodick, MD ABSTRACT Headache is a common condition, accounting for many specialist office visits annually.
More informationΣΥΓΚΛΕΙΣΗ ΑΝΟΙΚΤΟΥ ΩΟΕΙΔΟΥΣ ΤΡΗΜΑΤΟΣ ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC 33 Ο Πανελλήνιο Καρδιολογικό Συνζδριο ΑΘΗΝΑ 2012
ΣΥΓΚΛΕΙΣΗ ΑΝΟΙΚΤΟΥ ΩΟΕΙΔΟΥΣ ΤΡΗΜΑΤΟΣ 2012 ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC 33 Ο Πανελλήνιο Καρδιολογικό Συνζδριο ΑΘΗΝΑ 2012 The Problem: Not All PFO in Patients With Cryptogenic Stroke is Pathogenic; No Definitive
More informationPercutaneous Closure of Patent Foramen Ovale: A Case Series and Literature Review
Clinical Medicine & Research Volume 5, Number 4: 218-226 2007 Marshfield Clinic http://www.clinmedres.org Clinical Overview Percutaneous Closure of Patent Foramen Ovale: A Case Series and Literature Review
More informationAMPLATZER Septal Occluder Structural Heart Therapy. Over 15 years of. Demonstrated. Clinical Experience. We ll show you our data. Ask to see theirs.
AMPLATZER Septal Occluder Structural Heart Therapy Over 15 years of Demonstrated Clinical Experience We ll show you our data. Ask to see theirs. Leading the Standard of Care 1,2 The AMPLATZER Septal Occluder
More informationMedical Policy Surgical Treatment of Migraine Headache
Medical Policy Surgical Treatment of Migraine Headache Effective Date: January, 2011; Revised [7/13; 7/15] Subject: Surgical Treatment of Migraine Headache Overview: Several surgical treatments are being
More informationCongenital heart disease. By Dr Saima Ali Professor of pediatrics
Congenital heart disease By Dr Saima Ali Professor of pediatrics What is the most striking clinical finding in this child? Learning objectives By the end of this lecture, final year student should be able
More informationUNMH Pediatric Cardiology Clinical Privileges. Name: Effective Dates: From To
All new applicants must meet the following requirements as approved by the UNMH Board of Trustees, effective August 18, 2017: Initial Privileges (initial appointment) Renewal of Privileges (reappointment)
More informationPaediatrica Indonesiana
Paediatrica Indonesiana VOLUME 53 July NUMBER 4 Original Article Transcatheter vs. surgical closure of patent ductus arteriosus: outcomes and cost analysis Mulyadi M Djer, Mochammading, Mardjanis Said
More informationOutcomes Associated with the Off-label Use of Medical Devices in Congenital Heart Disease at a Single Institute
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Outcomes Associated with the Off-label Use of Medical Devices in Congenital Heart Disease at a Single Institute Young
More informationDEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending
DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE Matthew Starr, MD Stroke Attending DISCLOSURES None DEBATE Should PFO be closed? * * Sometimes yes THE CASE AGAINST PFO CLOSURE 1. Did the PFO cause the
More informationThe Patent Foramen Ovale A Preventable Stroke Etiology?! Brian Whisenant, M.D.
The Patent Foramen Ovale A Preventable Stroke Etiology?! Brian Whisenant, M.D. Conflict of Interest Statement I have a financial interest in Coherex Medical. Heart Disease and Stroke Statistics 2008 Update:
More informationDeterminants of Cardiopulmonary Functional Improvement After Transcatheter Atrial Septal Defect Closure in Asymptomatic Adults
Journal of the American College of Cardiology Vol. 43, No. 10, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.10.067
More informationPaediatrics Revision Session Cardiology. Emma Walker 7 th May 2016
Paediatrics Revision Session Cardiology Emma Walker 7 th May 2016 Cardiovascular Examination! General:! Make it fun!! Change how you act depending on their age! Introduction! Introduce yourself & check
More informationΔΙΑΧΕΙΡΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΜΕΣΟΚΟΛΠΙΚΗ ΕΠΙΚΟΙΝΩΝΙΑ ΖΑΧΑΡΑΚΗ ΑΓΓΕΛΙΚΗ ΚΑΡΔΙΟΛΟΓΟΣ ΗΡΑΚΛΕΙΟ - ΚΡΗΤΗ
ΔΙΑΧΕΙΡΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΜΕΣΟΚΟΛΠΙΚΗ ΕΠΙΚΟΙΝΩΝΙΑ ΖΑΧΑΡΑΚΗ ΑΓΓΕΛΙΚΗ ΚΑΡΔΙΟΛΟΓΟΣ ΗΡΑΚΛΕΙΟ - ΚΡΗΤΗ European Accreditation in TTE, TEE and CHD Echocardiography NOTHING TO DECLARE ATRIAL SEPTAL DEFECT TYPES SECUNDUM
More informationA challenging case of successful ASD closure without echocardiographic guidance in an 86-year old with severe kyphoscoliosis and platypnoeaorthodeoxia
A challenging case of successful ASD closure without echocardiographic guidance in an 86-year old with severe kyphoscoliosis and platypnoeaorthodeoxia syndrome. Dr Anvesha Singh, Dr James Ogle, Dr Derek
More information